<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18364" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Blastomycosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Miceli</surname>
            <given-names>Alyssa</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krishnamurthy</surname>
            <given-names>Karthik</given-names>
          </name>
          <aff>HCA Florida Orange Park Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alyssa Miceli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karthik Krishnamurthy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18364.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Blastomycosis is a fungal infection caused by Blastomyces dermatitidis. It presents as a pulmonary infection after the inhalation of spores, and it may be either asymptomatic or have severe life-threatening complications like acute respiratory distress syndrome. This activity reviews the evaluation and treatment of blastomycosis and explains the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify Blastomyces dermatitidis as the causal agent in the etiology of blastomycosis.</p></list-item><list-item><p>Summarize the pathophysiology of blastomycosis.</p></list-item><list-item><p>Review the most common adverse effects of amphotericin in the treatment of patients with blastomycosis.</p></list-item><list-item><p>Outline the importance of collaboration and communication among the interprofessional team members to enhance the delivery of care for patients affected by blastomycosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18364&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18364">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18364.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Blastomycosis is a fungal infection caused by the organism&#x000a0;<italic toggle="yes">Blastomyces dermatitidis</italic><italic toggle="yes">,&#x000a0;</italic>which is endemic in the soils of the Ohio and Mississippi River Valleys, Great Lakes region, and the southeastern United States.<xref ref-type="bibr" rid="article-18364.r1">[1]</xref> It most commonly presents as a pulmonary infection following the inhalation of spores, which may be asymptomatic and, therefore, undetectable, though severe, life-threatening complications like acute respiratory distress syndrome can occur. Extrapulmonary disease occurs in approximately 25% to 30% of patients after hematogenous dissemination from the lungs, with the skin being the most common site of extrapulmonary disease.<xref ref-type="bibr" rid="article-18364.r2">[2]</xref> Primary cutaneous blastomycosis, though rare, can occur due to direct inoculation after trauma to the skin. Unlike other deep fungal infections that occur predominantly in immunocompromised patients, blastomycosis also occurs in immunocompetent hosts.&#x000a0;<xref ref-type="bibr" rid="article-18364.r3">[3]</xref></p>
      </sec>
      <sec id="article-18364.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">Blastomyces&#x000a0;dermatitidis&#x000a0;</italic>is the causal agent of blastomycosis.<xref ref-type="bibr" rid="article-18364.r4">[4]</xref> A member of the phylum Ascomycota in the family Agellomycetaceae, it is recognized as the asexual state of&#x000a0;<italic toggle="yes">Ajellomyces&#x000a0;dermatitidis, </italic>a thermally dimorphic fungus<italic toggle="yes">. </italic>At 25 C, the mycelial form grows as a fluffy white mold, while at 37 C, it grows as a brown folded yeast. The&#x000a0;fungus can be isolated in the soil, where it forms a mycelium that penetrates the substratum on which it grows. &#x000a0;It reproduces asexually with small conidia that are 2-10&#x000a0;&#x000b5;m&#x000a0;in diameter. In infected cells,&#x000a0;<italic toggle="yes">Blastomycosis&#x000a0;</italic>dermatitidis<italic toggle="yes">&#x000a0;</italic>is seen as&#x000a0;budding yeast cells that are relatively large at 8 to 10 micrometers in diameter.<xref ref-type="bibr" rid="article-18364.r4">[4]</xref></p>
      </sec>
      <sec id="article-18364.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Blastomycosis is endemic in the Ohio and Mississippi River valleys, and near the Great Lakes and southeastern parts of the United States. The annual incidence is less than 1 case per 100,000 people in the commonly affected states of Mississippi, Kentucky, Arkansas, and Wisconsin.<xref ref-type="bibr" rid="article-18364.r5">[5]</xref> Other states commonly affected include North Carolina, Tennessee, Louisiana, and Illinois. Blastomycosis affects all ages, races, and genders, though it is reported to occur more frequently in males, presumably due to occupational and recreational exposures. Adult men are also more likely to develop systemic infection.</p>
      </sec>
      <sec id="article-18364.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The conidia, which can become aerosolized when the fungal colony is disturbed, are the main infectious particles produced by <italic toggle="yes">Blastomyces&#x000a0;dermatitidis.</italic> After conidia are inhaled, they pass into the lower respiratory tract. The conidia can be phagocytized by bronchopulmonary mononuclear cells and killed by neutrophils and macrophages, explaining the asymptomatic infection in some individuals.&#x000a0;<xref ref-type="bibr" rid="article-18364.r6">[6]</xref> When <italic toggle="yes">Blastomyces&#x000a0;dermatitidis</italic> converts to the yeast form, the thick wall provides resistance to phagocytosis and killing, which can result in symptomatic pulmonary infection. In addition, the immune-modulating glycoprotein BAD-1 facilitates its binding to macrophages, allowing dissemination through the blood and lymphatics to other areas of the body. The pyogranulomatous inflammatory response is a unique feature of blastomycosis and is caused by an influx of neutrophils, macrophages, and eventual granuloma formation.</p>
      </sec>
      <sec id="article-18364.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Initial symptoms of blastomycosis are flulike and typically resolve within days, though the patient may disregard their mild nature; therefore, the initial infection may go undiagnosed. In addition, asymptomatic infection occurs in about 50% of infected persons. Acute or chronic pneumonia can occur and, in elderly or immunocompromised patients, acute respiratory distress syndrome can result. The extrapulmonary disease can occur after the dissemination of <italic toggle="yes">Blastomyces&#x000a0;dermatitidis</italic> to other organs, with the skin being the most common site involved. Clinically, cutaneous blastomycosis typically starts as papules that evolve into crusted, vegetative plaques often with central clearing or ulceration. Lymphangitis and lymphadenopathy may be present. Bone lesions are the next most common finding, occurring in 25% of extrapulmonary cases, and are typically lytic. Though osteomyelitis can involve any bone, the lower spine and pelvis are most commonly affected. Other findings of an extrapulmonary disease can include prostatitis, orchitis, or epididymitis. The central nervous system is involved in 5% to 10% of cases, including cases of meningitis and intracranial or epidural abscesses.</p>
      </sec>
      <sec id="article-18364.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Direct visualization of <italic toggle="yes">Blastomyces&#x000a0;dermatitides </italic>is essential for a definitive diagnosis. Sputum specimens stained with 10% potassium hydroxide or a fungal stain have an approximate 80% yield. Biopsy and histopathological examination of skin lesions reveal pseudoepitheliomatous hyperplasia with neutrophilic abscesses. Organisms can be difficult to identify and are often found within histiocytes or abscesses in the dermis. The yeasts are 8 to 15 micrometers in diameter with thick, double-contoured walls and display broad-based budding. Culture is the most sensitive method for detecting and diagnosing blastomycosis. <xref ref-type="bibr" rid="article-18364.r4">[4]</xref>Growth is typically detected in 5 to 10 days but can take up to 30 days if few organisms are present in the specimen.</p>
        <p>Chest radiologic imaging can be used to&#x000a0;screen for pulmonary involvement, though findings are variable and lack specificity. Of all the systemic fungal infections, blastomycosis is most likely to resemble cancer on lung radiography. Lumbar puncture and cerebrospinal fluid analysis may be ensued to determine central nervous system involvement, though the diagnosis is also difficult and rarely definitive. Lastly, a chemiluminescent DNA probe is commercially available and can produce results within hours.<xref ref-type="bibr" rid="article-18364.r7">[7]</xref> It will, however, produce a positive result with <italic toggle="yes">Paracoccidioides brasiliensis</italic>, though this is usually not a problem in the US as this organism is found almost exclusively in South and Central America.</p>
      </sec>
      <sec id="article-18364.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Although spontaneous remission can occur, it is recommended that all patients with the mild or moderate disease be treated to avoid dissemination and recurrence. Itraconazole is the treatment of choice for all forms of the disease, except in severe, life-threatening cases. It is recommended that 600 mg be given orally daily for three days, followed by 200 mg to 400 mg per day for 6 to 12 months.<xref ref-type="bibr" rid="article-18364.r8">[8]</xref> Itraconazole has relatively low toxicity and good efficacy, though it is important to remember that gastric acidity is required for its absorption. Other azoles, including ketoconazole and fluconazole, can be used but are not preferred due to lower efficacy and, in the case of ketoconazole, a worse side effect profile.<xref ref-type="bibr" rid="article-18364.r9">[9]</xref> Voriconazole has good cerebrospinal fluid penetration and thus plays a role in CNS disease.&#x000a0;Azoles are contraindicated in pregnancy. Amphotericin B is used in severe and life-threatening diseases at a high dose of 0.7 to 1 mg/kg/day to a total dose of 1.5 to 2 grams. Liposomal amphotericin B at a dose of 3 to 5 mg/kg per day can alternatively be used for severe infection and is preferred for CNS blastomycosis and treatment in pregnant women.<xref ref-type="bibr" rid="article-18364.r8">[8]</xref><xref ref-type="bibr" rid="article-18364.r10">[10]</xref> Amphotericin is associated with several notable adverse effects, particularly renal impairment, which is less likely with the lipid formulation. Other adverse effects include hypokalemia, anemia, fever, chills, nausea, and thrombophlebitis at the injection site.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-18364.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of blastomycosis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pneumonia</p>
          </list-item>
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
          <list-item>
            <p>Non-infectious pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Cancer</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18364.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of patients who are immunocompetent is generally good as they have a decreased chance of suffering from complications of the infection. Successful treatment of this condition is achieved in approximately 80% to 95% of cases.</p>
        <p>On the other hand, immunocompromised patients with blastomycosis have poor prognosis.</p>
      </sec>
      <sec id="article-18364.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Relapse/disease recurrence</p>
          </list-item>
          <list-item>
            <p>Abscesses</p>
          </list-item>
          <list-item>
            <p>Skin sores</p>
          </list-item>
          <list-item>
            <p>Side effects of treatment (amphotericin)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18364.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Immunocompromised patients should be educated on the avoidance of areas and activities that are associated with an increased risk of this infection.</p>
      </sec>
      <sec id="article-18364.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of blastomycosis are complex and best done with an interprofessional team that includes the primary care provider, nurse practitioner, dermatologist, infectious disease expert, and a pulmonologist. The key is deciding on the treatment of patients with a mild disease because spontaneous remissions can occur. However, it is recommended that all patients with the mild or moderate disease be treated to avoid dissemination and recurrence. Itraconazole is the treatment of choice for all forms of the disease, except in severe, life-threatening cases. It is recommended that 600 mg be given orally daily for three days, followed by 200 to 400 mg per day for 6 to 12 months.<xref ref-type="bibr" rid="article-18364.r8">[8]</xref>&#x000a0;</p>
        <p>The outlook for healthy patients with blastomycosis is good, but the recovery may be prolonged. In immunocompromised individuals, the outcomes are guarded. <xref ref-type="bibr" rid="article-18364.r11">[11]</xref>(Level V)</p>
      </sec>
      <sec id="article-18364.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18364&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18364">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/blastomycosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18364">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18364/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18364">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18364.s15">
        <fig id="article-18364.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Chromoblastomycosis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="chromoblastomycosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18364.s16">
        <title>References</title>
        <ref id="article-18364.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Riddell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of endemic mycoses.</article-title>
            <source>Curr Infect Dis Rep</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>440</fpage>
            <page-range>440-9</page-range>
            <pub-id pub-id-type="pmid">23917880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Endemic blastomycosis in Mississippi: epidemiological and clinical studies.</article-title>
            <source>Semin Respir Infect</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-28</page-range>
            <pub-id pub-id-type="pmid">9313293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous inoculation blastomycosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2002</year>
            <month>May</month>
            <day>15</day>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>E44</fpage>
            <page-range>E44-9</page-range>
            <pub-id pub-id-type="pmid">11981746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saccente</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Clinical and laboratory update on blastomycosis.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>367</fpage>
            <page-range>367-81</page-range>
            <pub-id pub-id-type="pmid">20375357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Miceli</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Blastomycosis.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>247</fpage>
            <page-range>247-64</page-range>
            <pub-id pub-id-type="pmid">26739607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lohrenz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Minion</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karunakaran</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Blastomycosis in Southern Saskatchewan 2000-2015: Unique presentations and disease characteristics.</article-title>
            <source>Med Mycol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>787</fpage>
            <page-range>787-795</page-range>
            <pub-id pub-id-type="pmid">29924358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gattuso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>VB</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of blastomycosis in surgical pathology and cytopathology: correlation with microbiologic culture.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-61</page-range>
            <pub-id pub-id-type="pmid">20090507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goughenour</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Rappleye</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Antifungal therapeutics for dimorphic fungal pathogens.</article-title>
            <source>Virulence</source>
            <year>2017</year>
            <month>Feb</month>
            <day>17</day>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-221</page-range>
            <pub-id pub-id-type="pmid">27646561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lestner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>911</fpage>
            <page-range>911-26</page-range>
            <pub-id pub-id-type="pmid">23641752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halteh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Toussi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>DeLaMora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lipner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schuetz</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Blastomycosis during pregnancy: a case report and review of the literature.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-151</page-range>
            <pub-id pub-id-type="pmid">28291633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18364.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Embil</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goulet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Light</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Management and Outcomes of Acute Respiratory Distress Syndrome Caused by Blastomycosis: A Retrospective Case Series.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>May</month>
            <volume>95</volume>
            <issue>18</issue>
            <fpage>e3538</fpage>
            <pub-id pub-id-type="pmid">27149459</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
